By Reuters Staff August 22, 2019 NEW YORK (Reuters Health) - The direct-acting antiviral (DAA) combination of glecaprevir and pibrentasvir is effective in patients with genotype 1 hepatitis C virus (HCV) infection after failure of treatment with sofosbuvir plus an NS5A inhibitor, according to results from a new open-label trial. The combination of ...

My Name is Ayu Oktariani, I’m from Bandung, Indonesia, I am 29 years old female. I’m co-infection HIV HCV patient, since 2009. My HIV condition is very well managed since the time infected, the ARV therapy help me through the difficult time. But my HCV infection makes it harder, because ...